The choice between an older matched sibling donor (MSD) and a younger matched unrelated donor (MUD) in allogeneic hematopoietic cell transplantation remains the subject of ongoing debate. In this single-center retrospective study of 377 patients who received peripheral blood stem cell (PBSC) transplants for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), we compared outcomes of 85 patients who received grafts from MSD age >60 to 292 subjects who were transplanted using a MUD age <30. Compared to subjects with a MSD, patients who received MUD transplants were younger, and were more likely to receive dual T-cell depletion (TCD), higher CD34+ cell dose and a fresh graft. Recipients of MSD transplants were maintained on immunosuppressive therapy longer than those who received MUD grafts. We report no difference in overall survival, relapse-free survival, graft-vs-host disease (GVHD)- and relapse-free survival, non-relapse mortality, relapse, engraftment, graft failure or acute GVHD between recipients of MSD and MUD grafts. We report a higher 30-d but not 1-y incidence of blood stream infections among recipients of MUD transplants compared to subjects who received their grafts from a MUD. The incidence of moderate-severe chronic GVHD was higher in MSD compared with MUD transplants in univariate but not multivariate analysis. Whereas this difference could reflect the higher use of dual TCD, a combination known to be associated with very low rates of chronic GVHD in MUD transplants, the incidence of moderate-severe chronic GVHD was no different between MSD and MUD transplants following propensity score matching, suggesting that other variables could be responsible. Taken together, our data suggests in the case of patients with AML or MDS who receive PBSC transplants, such factors as convenience, ease of access and costs should be considered in selecting an older MSD over a younger MUD.
22 May 2023 in Hematology, Transfusion and Cell Therapy
Introduction: The time elapsed from diagnosis to hematopoietic stem cell transplantation (HSCT) is influenced by numerous factors. In Brazil, patients using the public health system are also dependent on the availability of HSCT-specific beds in the hematology ward. Objective and Methods We conducted a cohort study of listed patients who underwent allogeneic HSCT at a Brazilian public hospital to investigate the impact of the waitlist time on post-HSCT survival. Results: The median time from diagnosis to HSCT was 19 months (IQR, 10 - 43), of which 6 months (IQR, 3 - 9) were spent on the waitlist. The time on the waitlist for HSCT appeared to influence mainly the survival of adult patients (≥ 18 years), with an increasing risk according to this time (RR, 3.53 and 95%CI, 1.81 - 6.88 for > 3 and ≤ 6 months; RR 5.86 and 95%CI, 3.26 - 10.53 for > 6 and ≤ 12 months, and; RR 4.24 and 95%CI, 2.32 - 7.75 for > 12 months). Conclusion: Patients who remained on the waitlist for less than 3 months had the highest survival (median survival, 856 days; IQR, 131 - 1607). The risk of reduced survival was about 6-fold higher (95%CI, 2.8 - 11.5) in patients with malignancies.
1 April 2023 in Hematology, Transfusion and Cell Therapy
Although extracorporeal photopheresis (ECP) is a promising second-line therapy in the treatment of chronic graft-versus-host disease (cGVHD), its use is limited by its high cost. This study aims to describe the clinical evolution of patients who underwent ECP therapy for cGVHD and to perform an economic analysis of the therapy This was a case series between 2016 and 2020 describing the clinical response to ECP and a micro-cost analysis of the therapy using time-driven activity-based costing. Six patients underwent ECP for corticosteroid-dependent cGVHD The cost per ECP session is 14,960.90 Brazilian reais (BRL), which primarily consists of the ECP kit with an activator (82.78%), followed by the hospital's physical structure (14.66%), human resources (2.48%) and exams/inputs (0.08%). The number of sessions performed ranged from 2 to 42. The total cost of the therapy per patient ranged from BRL 30,000 to 500,000. The response of the patient with cGVHD to treatment with ECP was variable. These micro-costing results can be used to develop remuneration and cost control strategies in hematopoietic stem cell transplantation programs, as well as in further economic studies.
Background/Objectives: Smoking is linked to an increased risk of pulmonary complications and adverse outcomes following allogeneic hematopoietic cell transplantation (Allo-HCT). Unfortunately, data is rarely correlated with the incidence of GVHD and does not show whether smoking has a negative impact independent from underlying pulmonary comorbidities. Methods: We retrospectively analyzed 407 patients who underwent Allo-HCT between January 2019 and May 2021 and evaluated the impact of smoking history and pre-transplant pulmonary comorbidities on the risk of outcomes including graft-versus-host disease (GVHD), overall survival (OS), and non-relapse mortality (NRM). Results: Patients were divided into the following groups: Group A: smokers with pre-transplant pulmonary comorbidity, 40 pts (9.8%); Group B: non-smokers with pre-transplant pulmonary comorbidity, 71 pts (17.4%); Group C: smokers without pre-transplant pulmonary comorbidity, 105 pts (25.8%); and Group D: non-smokers without pre-transplant pulmonary comorbidity, 191 pts (46.9%). Smokers were also grouped by their smoking history (25 pack-years (35 pts)) and by smoking recency: Recent (until Allo-HCT), Former (quit > 1 year ago), and Remote smokers (quit > 10 years ago). Our results showed that Group A demonstrated increased chronic lung GVHD compared to the other groups (p = 0.01). The 3-year OS was lowest in Group A at 45.0%, compared to 70.4%, 62.4%, and 69.4% (p = 0.006), and the NRM was highest at 37.5%, compared to 15.5%, 18.2%, and 14.7% in Groups B, C, and D, respectively (p = 0.001). Smoking recency and higher pack-year dose were associated with worse outcomes. Conclusions: Our study demonstrated the negative synergistic effect of smoking history and pre-transplant pulmonary comorbidities on the incidence of lung GVHD, OS, and NRM.
8 January 2026 in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
This document updates the 2023 Brazilian Society of Cell Therapy and Bone Marrow Transplantation (SBTMO) consensus on allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML), incorporating the 2022 and 2024 European LeukemiaNet (ELN) risk classifications, the 2025 ELN-DAVID measurable residual disease (MRD) recommendations, recent induction trials, and the 2025 European Society for Blood and Marrow Transplantation (EBMT) transplant indications. MRD monitoring, assessed by quantitative polymerase chain reaaction, next-generation sequencing, or multiparameter flow cytometry, now guides transplant timing alongside ELN risk category, refining decisions in intermediate-risk patients and informing pre- and post-transplant management. Allogeneic HSCT remains indicated for adverse-risk AML and second complete remission regardless of MRD status, while favorable-risk patients generally avoid transplant unless MRD persists after consolidation. For elderly patients, chronological age alone should not exclude HSCT candidacy; comprehensive geriatric assessment and alternative donor sources have expanded access, supported by Brazilian regulatory changes raising the eligibility age to 75. Conditioning strategy, graft-versus-host disease prophylaxis with post-transplant cyclophosphamide, stem cell source selection, and donor immunogenetic screening are addressed, alongside emerging post-transplant maintenance therapies for high-risk molecular subgroups. Novel cellular therapies— CAR-T and CAR-NK cells—remain investigational, limited by antigen escape and short persistence, requiring consolidation with allogeneic HSCT. This consensus provides evidence-graded recommendations to standardize transplant decisionmaking for AML across Brazilian centers, reflecting the rapidly evolving therapeutic and diagnostic landscape.